Question 1

What is COSIBELIMAB used for?

Accepted Answer

COSIBELIMAB (brand name UNLOXCYT) is a Other indicated for See full prescribing information.

Question 2

How does COSIBELIMAB work?

Accepted Answer

COSIBELIMAB works through the following mechanism: 12.1. Mechanism of Action PD-L1 may be expressed on tumor cells and tumor-infiltrating immune cells and can contribute to the inhibition of the anti-tumor immune response in the tumor microenvironment. Binding of PD-L1 to the PD-1 and B7.1 receptors found on T cells and antigen presenting cells suppresses cytotoxic T-cell activity, T-cell proliferation, and cytokine production. Cosibelimab-ipdl binds PD-L1 and blocks the interaction between PD-L1 and its receptors PD-1 and B7.1. This interaction releases the inhibitory effects of PD-L1 on the anti-tumor immune response. Cosibelimab-ipdl has also been shown to induce antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro..

Question 3

What are the most common side effects of COSIBELIMAB?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for COSIBELIMAB. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is COSIBELIMAB the same as UNLOXCYT?

Accepted Answer

UNLOXCYT is a brand name for COSIBELIMAB. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

COSIBELIMAB

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations